# Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC

- Source: PR Newswire M&A
- Published: 2026-11-06T14:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/combinations-of-ioncturas-roginolisib-revert-immune-suppression-in-immunotherapy-resistant-nsclc-302931987.html
- Canonical: https://groundlevelnews.com/story/combinations-of-ionctura-s-roginolisib-revert-immune-suppression-in-im-7dd22e/

Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC Data demonstrated roginolisib-containing regimens were tolerable, reduced...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._